drugset / Trial / NCT07459634
A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of lurbinectedin in combination with durvalumab for the treatment of participants with extensive stage small cell lung cancer (ES-SCLC) whose disease has not progressed after first line (1L) induction therapy.
Timeline
- Start
- 2026-08-30
- Primary completion
- 2028-01-31
- Completion
- 2028-04-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Durvalumab | Monoclonal antibody | — | Intravenous |
| Subject | Lurbinectedin | Other / unclassified | — | Intravenous |